4
Changes in Ownership
Trevi Therapeutics, Inc. Filed Acc 0001209191-23-018875
Chief Financial Officer sold 892 shares at $1.75 ($1,564)
- Chief Financial Officer acquired 2,291 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Delfini Lisa · Chief Financial Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-03-13 | Exercise or conversion : show line 1 in the form | +2,291 | $0.51 | $1,171 | 25,629 | D |
| 2023-03-13 | Sale : show line 2 in the form | −892 | $1.75 | $1,564 | 24,737 | D |
| Open-market sales · 892 sh · avg $1.75 · $1,564 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2023-03-13 | Exercise or conversion : show line 3 in the form Stock Option (right to buy) | −2,291 | 80,209 | D |
Loading xslF345X03/doc4.xml…